These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
309 related articles for article (PubMed ID: 32323152)
1. The Role of VPS35 in the Pathobiology of Parkinson's Disease. Sassone J; Reale C; Dati G; Regoni M; Pellecchia MT; Garavaglia B Cell Mol Neurobiol; 2021 Mar; 41(2):199-227. PubMed ID: 32323152 [TBL] [Abstract][Full Text] [Related]
2. VPS35, the Retromer Complex and Parkinson's Disease. Williams ET; Chen X; Moore DJ J Parkinsons Dis; 2017; 7(2):219-233. PubMed ID: 28222538 [TBL] [Abstract][Full Text] [Related]
3. An update on cellular and molecular determinants of Parkinson's disease with emphasis on the role of the retromer complex. Macías-Calvio V; Fuentealba LM; Marzolo MP J Neurosci Res; 2021 Jan; 99(1):163-179. PubMed ID: 32633426 [TBL] [Abstract][Full Text] [Related]
4. Parkin mediates the ubiquitination of VPS35 and modulates retromer-dependent endosomal sorting. Williams ET; Glauser L; Tsika E; Jiang H; Islam S; Moore DJ Hum Mol Genet; 2018 Sep; 27(18):3189-3205. PubMed ID: 29893854 [TBL] [Abstract][Full Text] [Related]
5. VPS35 and retromer dysfunction in Parkinson's disease. Rowlands J; Moore DJ Philos Trans R Soc Lond B Biol Sci; 2024 Apr; 379(1899):20220384. PubMed ID: 38368930 [TBL] [Abstract][Full Text] [Related]
6. Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration. Tsika E; Glauser L; Moser R; Fiser A; Daniel G; Sheerin UM; Lees A; Troncoso JC; Lewis PA; Bandopadhyay R; Schneider BL; Moore DJ Hum Mol Genet; 2014 Sep; 23(17):4621-38. PubMed ID: 24740878 [TBL] [Abstract][Full Text] [Related]
7. VPS35 and α-Synuclein fail to interact to modulate neurodegeneration in rodent models of Parkinson's disease. Chen X; Tsika E; Levine N; Moore DJ Mol Neurodegener; 2023 Aug; 18(1):51. PubMed ID: 37542299 [TBL] [Abstract][Full Text] [Related]
8. VPS35 in Dopamine Neurons Is Required for Endosome-to-Golgi Retrieval of Lamp2a, a Receptor of Chaperone-Mediated Autophagy That Is Critical for α-Synuclein Degradation and Prevention of Pathogenesis of Parkinson's Disease. Tang FL; Erion JR; Tian Y; Liu W; Yin DM; Ye J; Tang B; Mei L; Xiong WC J Neurosci; 2015 Jul; 35(29):10613-28. PubMed ID: 26203154 [TBL] [Abstract][Full Text] [Related]
9. Endosomal dysfunction in iPSC-derived neural cells from Parkinson's disease patients with VPS35 D620N. Bono K; Hara-Miyauchi C; Sumi S; Oka H; Iguchi Y; Okano HJ Mol Brain; 2020 Oct; 13(1):137. PubMed ID: 33032646 [TBL] [Abstract][Full Text] [Related]
10. Parkinson's disease-linked Chen X; Kordich JK; Williams ET; Levine N; Cole-Strauss A; Marshall L; Labrie V; Ma J; Lipton JW; Moore DJ Proc Natl Acad Sci U S A; 2019 Mar; 116(12):5765-5774. PubMed ID: 30842285 [TBL] [Abstract][Full Text] [Related]
11. VPS35 and the mitochondria: Connecting the dots in Parkinson's disease pathophysiology. Cutillo G; Simon DK; Eleuteri S Neurobiol Dis; 2020 Nov; 145():105056. PubMed ID: 32853677 [TBL] [Abstract][Full Text] [Related]
12. Vps35 in cooperation with LRRK2 regulates synaptic vesicle endocytosis through the endosomal pathway in Drosophila. Inoshita T; Arano T; Hosaka Y; Meng H; Umezaki Y; Kosugi S; Morimoto T; Koike M; Chang HY; Imai Y; Hattori N Hum Mol Genet; 2017 Aug; 26(15):2933-2948. PubMed ID: 28482024 [TBL] [Abstract][Full Text] [Related]
13. VPS35 pathogenic mutations confer no dominant toxicity but partial loss of function in Drosophila and genetically interact with parkin. Malik BR; Godena VK; Whitworth AJ Hum Mol Genet; 2015 Nov; 24(21):6106-17. PubMed ID: 26251041 [TBL] [Abstract][Full Text] [Related]
14. The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human. Mir R; Tonelli F; Lis P; Macartney T; Polinski NK; Martinez TN; Chou MY; Howden AJM; König T; Hotzy C; Milenkovic I; Brücke T; Zimprich A; Sammler E; Alessi DR Biochem J; 2018 Jun; 475(11):1861-1883. PubMed ID: 29743203 [TBL] [Abstract][Full Text] [Related]
15. (D620N) VPS35 causes the impairment of Wnt/β-catenin signaling cascade and mitochondrial dysfunction in a PARK17 knockin mouse model. Chiu CC; Weng YH; Huang YZ; Chen RS; Liu YC; Yeh TH; Lu CS; Lin YW; Chen YJ; Hsu CC; Chiu CH; Wang YT; Chen WS; Liu SY; Wang HL Cell Death Dis; 2020 Nov; 11(11):1018. PubMed ID: 33257649 [TBL] [Abstract][Full Text] [Related]
16. VPS35 Deficiency or Mutation Causes Dopaminergic Neuronal Loss by Impairing Mitochondrial Fusion and Function. Tang FL; Liu W; Hu JX; Erion JR; Ye J; Mei L; Xiong WC Cell Rep; 2015 Sep; 12(10):1631-43. PubMed ID: 26321632 [TBL] [Abstract][Full Text] [Related]
17. VPS35 regulates parkin substrate AIMP2 toxicity by facilitating lysosomal clearance of AIMP2. Yun SP; Kim H; Ham S; Kwon SH; Lee GH; Shin JH; Lee SH; Ko HS; Lee Y Cell Death Dis; 2017 Apr; 8(4):e2741. PubMed ID: 28383562 [TBL] [Abstract][Full Text] [Related]
18. Mechanisms of Sargent D; Moore DJ Int Rev Mov Disord; 2021; 2():221-244. PubMed ID: 35497708 [TBL] [Abstract][Full Text] [Related]
19. Understanding the contributions of VPS35 and the retromer in neurodegenerative disease. Williams ET; Chen X; Otero PA; Moore DJ Neurobiol Dis; 2022 Aug; 170():105768. PubMed ID: 35588987 [TBL] [Abstract][Full Text] [Related]
20. VPS35 dysfunction impairs lysosomal degradation of α-synuclein and exacerbates neurotoxicity in a Drosophila model of Parkinson's disease. Miura E; Hasegawa T; Konno M; Suzuki M; Sugeno N; Fujikake N; Geisler S; Tabuchi M; Oshima R; Kikuchi A; Baba T; Wada K; Nagai Y; Takeda A; Aoki M Neurobiol Dis; 2014 Nov; 71():1-13. PubMed ID: 25107340 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]